Cure Today4h
CAR T-Cell Therapy Yescarta Continues to Demonstrate Durable Responses in Follicular Lymphoma
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.
Scientists unveil surprising human vs. mouse differences in a major cancer immunotherapy target
Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...
CaMKIIβ key in transducing Ca²⁺ transients to initiate autophagosome formation: Study
Transient Ca2+ fluctuations on the surface of the endoplasmic reticulum (ER) can induce liquid-liquid phase separation (LLPS) ...
FDA approves Gemtesa for overactive bladder in men with benign prostatic hyperplasia
Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...